It is used as one of a few experimental treatments for patients with deadly pancreatic cancer when the main chemotherapeutic treatment regimen of gemcitabine is no longer useful.
This treatment is utilized in a limited capacity as an alternative approach for patients with terminal pancreatic cancer, particularly those whose standard chemotherapy regimen of gemcitabine has reached a point of diminishing returns.